What's Going With Apellis Pharmaceuticals Stock Friday?
Portfolio Pulse from Dylan Berman
Apellis Pharmaceuticals' stock is declining after the European Medicines Agency's CHMP confirmed its negative opinion on the marketing authorization for pegcetacoplan, a treatment for geographic atrophy. This decision impacts millions of Europeans with this form of blindness.
September 20, 2024 | 2:45 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Apellis Pharmaceuticals' stock is down 10.5% following the CHMP's reaffirmation of a negative opinion on pegcetacoplan for geographic atrophy treatment. This decision is a setback for the company, affecting its market position in Europe.
The CHMP's decision directly impacts Apellis Pharmaceuticals as it prevents the company from marketing pegcetacoplan in Europe, a significant market. This regulatory setback is likely to negatively affect investor sentiment and the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100